Skip to content
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Menu
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Menu
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
You are currently viewing Harvard takes a new trip into the world of psychedelic drugs

Harvard takes a new trip into the world of psychedelic drugs

  • Post author:Olly PP
  • Post published:February 23, 2022
  • Post category:Industry News
Tags: Industry Media

Read more articles

Previous PostAfter Its Vilification In The 1960s, There Is Now A Renaissance In Psychedelic Drugs To Help Treat Depression And Mental Health Issues
Next PostPersisting decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees

You Might Also Like

Read more about the article New study looks at ‘magic’ mushrooms as treatment for depression, without the psychedelic high

New study looks at ‘magic’ mushrooms as treatment for depression, without the psychedelic high

July 27, 2022
Read more about the article Brexit Britain becomes unlikely psychedelic haven as Albert Labs IPOs

Brexit Britain becomes unlikely psychedelic haven as Albert Labs IPOs

March 10, 2022
Read more about the article Persisting decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees

Persisting decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees

March 2, 2022

Recent Posts

  • Albert Labs Welcomes Dr. Shabir Hasham to Board of Directors
  • Albert Labs Management and Board of Director Announcement
  • Albert Labs Receives preliminary acceptance of 35 Novel Inventive Claims for Patent Protected Manufacturing Technology
  • Expansion of Drug Discovery and a Promising Pipeline
  • Albert Labs Announces Private Placement

Recent Comments

  • Randal Elliott on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Nicholas Stewart on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Camille Ortega on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Kelly Lambert on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Dean Phillips on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker

Innovative mental health medicines for patients with unmet needs

  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy

© 2024 Albert Labs. All Rights Reserved

  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Twitter Linkedin Youtube Envelope
CSE:ABRT
FSE: VB50
CSE:ABRT
FSE: VB50

About Albert Labs

We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

If you would like support or more information around making an investment, please contact [email protected]

Twitter Linkedin Youtube Envelope

Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

  • This field is for validation purposes and should be left unchanged.
Twitter
Youtube
Linkedin
Instagram
Envelope
Twitter
Youtube
Linkedin
Instagram
Envelope

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.